Clinical Trial Update: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating cobolimab + dostarlimab + docetaxel versus dostarlimab + docetaxel and docetaxel alone in advanced non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cobolimab (cobolimab)
• DOCETAXEL (DOCETAXEL)
• Dostarlimab (dostarlimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING